Medical Oncology

University of Washington

University of Washington tumor board

Questions discussed in this category

Is there still a role for plasma exchange/PLEX for confirmed or suspected cast nephropathy in multiple myeloma to rapidly reduce light chain burden?

In addition to reversing hypercalcemia, initiating myeloma therapy, etc.

1 Answer available

For patients with IgG kappa multiple myeloma receiving an IgG kappa mAb (i.e., daratumumab), how important is it clinically to use an interference assay if they're in a VGPR to see if their M-spike might actually be 0?

For example, would you use a tool like the Hydrashift assay? Would this change your management?

1 Answer available

When you use selinexor for relapsed/refractory myeloma, with what total weekly dose do you practically start?

If tolerated through Cycle #1, how aggressively do you try to titrate the selinexor dose up toward 100mg weekly or 80mg twice-weekly? And does your a...

1 Answer available

If you treat a patient with high-risk smoldering myeloma on trial and they develop biochemical progression by M-spike, but still no CRAB-SLiM criteria, what would you do next?

In this case, the patient had received daratumumab/lenalidomide/dexamethasone as part of a cooperative group trial. Would you say that the patient had...

1 Answer available

What induction regimen would you choose for a patient with newly diagnosed multiple myeloma with incidental amyloidosis noted on bone marrow biopsy, but with no end-organ damage as a result of amyloid deposition?

Would you consider Dara-CyBorD or a MM triplet/quadruplet such as VRd or Dara-VRd?

4 Answers available